• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫检查点抑制剂毒性的机制分类作为进一步提高生存率的最小治疗策略的指针。

Mechanistic classification of immune checkpoint inhibitor toxicity as a pointer to minimal treatment strategies to further improve survival.

机构信息

Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, Chapel Allerton Hospital, Leeds, UK.

Department of Medicine 'B', Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

出版信息

Autoimmun Rev. 2020 Feb;19(2):102456. doi: 10.1016/j.autrev.2019.102456. Epub 2019 Dec 12.

DOI:10.1016/j.autrev.2019.102456
PMID:31838166
Abstract

Improved anti-tumour responses under immune checkpoint inhibition (ICI) are associated with concomitant autoimmune disease development termed immune related adverse events (irAEs), of which approximately 5% are rheumatic in nature. Generally, oncologists and other specialists vigorously treat irAEs in spite of the generally accepted beneficial effect of irAEs on tumour survival. Herein, we highlight mechanistic insights on how tumour responses and certain types of autoimmunity appear to be inextricably linked around CD8+ T-cell mediated responses and that strategies that interfere with such shared immunopathgenesis could impact of survival. We discuss the possible circumstances in which intensive immunosuppressive therapy for irAEs that occur with ICIs might blunt anti-tumour immunity. We also discuss potential therapeutic strategies for emergent ICI related autoimmunity and propose some treatment considerations and research questions to minimize the impact of overzealous immunosuppression strategies on tumour responses. Thus, refraining from using powerful therapeutic armamentarium to treat irAEs, especially when these are not considered as life-threating might improve the prognosis of ICI therapy.

摘要

免疫检查点抑制(ICI)下抗肿瘤反应的改善与同时发生的自身免疫性疾病发展有关,称为免疫相关不良事件(irAEs),其中约 5%为风湿性。通常,肿瘤学家和其他专家会积极治疗 irAEs,尽管 irAEs 对肿瘤生存的普遍有益影响已被普遍接受。在此,我们强调了关于肿瘤反应和某些类型的自身免疫如何似乎与 CD8+T 细胞介导的反应密切相关的机制见解,以及干扰这种共同免疫发病机制的策略可能会影响生存。我们讨论了在 ICI 中发生的 irAEs 进行强化免疫抑制治疗可能会削弱抗肿瘤免疫的可能情况。我们还讨论了新兴的 ICI 相关自身免疫的潜在治疗策略,并提出了一些治疗注意事项和研究问题,以最大程度地减少过度免疫抑制策略对肿瘤反应的影响。因此,避免使用强大的治疗武器来治疗 irAEs,尤其是当这些治疗不会危及生命时,可能会改善 ICI 治疗的预后。

相似文献

1
Mechanistic classification of immune checkpoint inhibitor toxicity as a pointer to minimal treatment strategies to further improve survival.免疫检查点抑制剂毒性的机制分类作为进一步提高生存率的最小治疗策略的指针。
Autoimmun Rev. 2020 Feb;19(2):102456. doi: 10.1016/j.autrev.2019.102456. Epub 2019 Dec 12.
2
Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.平衡癌症免疫疗法和免疫相关不良事件:调节性 T 细胞的新作用。
J Autoimmun. 2019 Nov;104:102310. doi: 10.1016/j.jaut.2019.102310. Epub 2019 Aug 15.
3
Autoimmunity in immune checkpoint inhibitor-induced immune-related adverse events: A focus on autoimmune skin toxicity and pneumonitis.免疫检查点抑制剂引起的免疫相关不良反应中的自身免疫:重点关注自身免疫性皮肤毒性和肺炎。
Immunol Rev. 2023 Sep;318(1):37-50. doi: 10.1111/imr.13258. Epub 2023 Aug 7.
4
Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review.自身免疫、检查点抑制剂治疗和免疫相关不良事件:综述。
Semin Cancer Biol. 2020 Aug;64:93-101. doi: 10.1016/j.semcancer.2019.06.012. Epub 2019 Jul 19.
5
Immune and autoimmune-related adverse events associated with immune checkpoint inhibitors in cancer therapy.癌症治疗中与免疫检查点抑制剂相关的免疫及自身免疫相关不良事件。
Drugs Today (Barc). 2018 Feb;54(2):103-122. doi: 10.1358/dot.2018.54.2.2776626.
6
Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy.癌症免疫治疗中与免疫检查点抑制剂相关的风湿性疾病。
Mod Rheumatol. 2019 Sep;29(5):721-732. doi: 10.1080/14397595.2018.1532559. Epub 2018 Dec 20.
7
Immune checkpoint inhibitor combinations: Current efforts and important aspects for success.免疫检查点抑制剂联合治疗:当前的努力和成功的重要方面。
Drug Resist Updat. 2019 Jul;45:13-29. doi: 10.1016/j.drup.2019.07.004. Epub 2019 Jul 29.
8
Immune-related adverse events after immune check point inhibitors: Understanding the intersection with autoimmunity.免疫检查点抑制剂治疗后的免疫相关不良反应:了解与自身免疫的交集。
Immunol Rev. 2023 Sep;318(1):81-88. doi: 10.1111/imr.13247. Epub 2023 Jul 26.
9
Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life.检查点抑制剂治疗停止后持续存在的免疫相关不良事件:患病率及其对患者健康相关生活质量的影响。
Eur J Cancer. 2022 Nov;176:88-99. doi: 10.1016/j.ejca.2022.08.029. Epub 2022 Oct 2.
10
Immunotherapy to treat malignancy in patients with pre-existing autoimmunity.免疫疗法治疗伴有自身免疫的恶性肿瘤患者。
J Immunother Cancer. 2020 Apr;8(1). doi: 10.1136/jitc-2019-000356.

引用本文的文献

1
Immunotherapy improves disease prognosis by affecting the tumor microenvironment: A bibliometric study.免疫疗法通过影响肿瘤微环境来改善疾病预后:文献计量学研究。
Front Immunol. 2022 Oct 6;13:967076. doi: 10.3389/fimmu.2022.967076. eCollection 2022.
2
Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment.病毒性和自身免疫性肝病中的肝细胞癌:免疫微环境中 CD4+CD25+Foxp3+调节性 T 细胞的作用。
World J Gastroenterol. 2021 Jun 14;27(22):2994-3009. doi: 10.3748/wjg.v27.i22.2994.
3
Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies.
基于抗检查点抑制剂抗体的联合抗癌策略
Antibodies (Basel). 2020 May 20;9(2):17. doi: 10.3390/antib9020017.